The most successful clinical trials have one thing in common: sponsors never stop looking for ways to improve processes that support the core objective of delivering safe, compliant investigational product to patients, when and where they need it.

This was the case for one pharmaceutical company, who was working to refine its trial drug formula from frozen liquid form to lyophilised powder without disrupting its global, phase II study. Read our latest case study to learn how Almac helped the sponsor effectively manage the drug formulation change mid-trial without study interruptions or patient impact.